Therapeuticsmd Inc (TXMD) 7.17 $TXMD TherapeuticsMD to

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:52 PM

Therapeuticsmd Inc (TXMD) 7.17 $TXMD

TherapeuticsMD to Host First Quarter 2015 Financial Results Conference Call and Webcast May 5
Business Wire - Wed Apr 22, 3:05PM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced that it will hold a conference call and live audio webcast to discuss first quarter 2015 financial and business results on Tuesday, May 5. The conference call and webcast will take place at 4:30 p.m. EDT. TherapeuticsMD CEO Robert G. Finizio and Chief Financial Officer Dan Cartwright will host the call.
TXMD: 7.17 (+0.01)

TherapeuticsMD (TXMD) Highlighted As Weak On High Volume
at The Street - Thu Apr 02, 9:08AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a weak on high relative volume candidate
TXMD: 7.17 (+0.01)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 8:13AM CDT

KMX: 70.84 (-0.04), CARB: 11.14 (-0.07), TXMD: 7.17 (+0.01), CERU: 5.99 (-0.20), CNAT: 6.31 (-0.15), RPRX: 8.36 (-0.15), LBIO: 12.50 (+0.50), FXCM: 2.13 (+0.02), CAPN: 6.99 (-0.29), WBAI: 16.75 (-0.46)

Technical Commentary on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Depomed, TherapeuticsMD, and Aoxing Pharma
PR Newswire - Thu Apr 02, 7:35AM CDT
Editor Note: For more information about this release, please scroll to bottom.
JNJ: 100.43 (+0.13), TXMD: 7.17 (+0.01), DEPO: 27.14 (+0.65), TEVA: 63.01 (-1.15), AXN: 1.77 (+0.01)

There Is Too Much Stock Supply - Cramer's Mad Money (4/1/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 02, 6:43AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, April 1. The elements of the stock market could be changing. Cramer spoke about the mechanics of money management, to teach investors about a new trend that...
ABT: 48.35 (+1.23), TXMD: 7.17 (+0.01), FRPT: 22.79 (-0.60), FUN: 56.97 (+0.81), MCD: 97.84 (+2.97), WFC: 54.67 (+0.39), BAC: 15.74 (+0.24), SIX: 49.97 (+1.37), ETSY: 25.12 (-0.63), BURL: 55.82 (+0.09), GDDY: 24.77 (-0.01)

Jim Cramer's Top Takeaways: GoDaddy, FreshPet, TherapeuticsMD
at The Street - Thu Apr 02, 5:00AM CDT
Cramer is no fan of GoDaddy but likes FreshPet's place in the healthy and organic food movement.
TXMD: 7.17 (+0.01), FRPT: 22.79 (-0.60), GDDY: 24.77 (-0.01)

Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
at The Street - Wed Apr 01, 7:22PM CDT
Supply is the true enemy of the bull and there's a lot of new supply hitting the markets, Cramer says.
CXO: 123.60 (+0.33), KMI: 44.07 (+0.46), TSLA: 219.44 (+10.03), KSS: 75.91 (+0.96), GE: 26.91 (+0.29), EMES: 51.50 (+0.20), FRPT: 22.79 (-0.60), UTX: 116.96 (+0.01), UNH: 117.81 (-1.47), FCX: 20.57 (+0.34), BPT: 67.68 (+1.51), SDRL: 11.33 (+0.28), SLB: 92.16 (+0.87), SBUX: 48.33 (-0.04), DNKN: 47.72 (+0.21), INSY: 62.10 (+0.76), LNCO: 12.34 (+0.46), AMAT: 22.31 (+0.02), CRZO: 52.72 (+0.32), FGP: 23.82 (+0.22), AAPL: 128.62 (+1.71), SIRI: 3.94 (unch), ABT: 48.35 (+1.23), MCK: 231.27 (-0.02), BMY: 66.60 (-0.21), ALK: 64.31 (-0.62), ARP: 9.04 (-0.02), URBN: 42.17 (+0.03), DDS: 136.44 (-0.34), AGEN: 6.08 (+0.21), PM: 83.69 (-0.36), HCA: 77.53 (-0.15), RDS.A: 62.36 (-0.06), TXMD: 7.17 (+0.01), BIG: 47.15 (+0.11), GDDY: 24.77 (-0.01), KPTI: 32.24 (-0.60)

Interesting TXMD Put And Call Options For May 15th
DividendChannel.com - Tue Mar 24, 10:55AM CDT
Investors in TherapeuticsMD, Inc. saw new options become available this week, for the May 15th expiration.
TXMD: 7.17 (+0.01)

Strong On High Volume: TherapeuticsMD (TXMD)
at The Street - Thu Mar 19, 9:00AM CDT
Trade-Ideas LLC identified TherapeuticsMD (TXMD) as a strong on high relative volume candidate
TXMD: 7.17 (+0.01)

TherapeuticsMD Appoints Biopharmaceutical Senior Executives Angus C. Russell and J. Martin Carroll as Independent Directors
Business Wire - Wed Mar 18, 7:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT:TXMD), an innovative women's healthcare company, announced today the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors.
TXMD: 7.17 (+0.01), SHPG: 253.58 (+3.70), RVNC: 22.31 (-0.58)

TherapeuticsMD incurs higher net operating loss of USD54.2m in 2014
M2 - Wed Mar 11, 4:56AM CDT
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) disclosed on Tuesday its net operating loss of USD54.2m (USD0.36 per basic and diluted share) for the period ending 31 December 2014.
TXMD: 7.17 (+0.01)

TherapeuticsMD's (TXMD) CEO Rob Finizio on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 10, 9:22PM CDT

TXMD: 7.17 (+0.01)

THERAPEUTICSMD
at Investor's Business Daily - Tue Mar 10, 5:58PM CDT
THERAPEUTICSMD (TXMD), a women's health care company, reported a Q4 per-share loss of 10 cents vs. a 6-cent loss a year ago, missing views for a 9-cent loss. Sales grew 49% to $4.26 mil, below estimates of $4.35 mil. Shares rose 6.2% to 5.32.
TXMD: 7.17 (+0.01)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 4:38PM CDT

MACK: 13.44 (+0.18), MHR: 2.34 (-0.07), WB: 16.09 (+1.56), TXMD: 7.17 (+0.01), ANTH: 4.79 (+0.10), HABT: 33.00 (+0.55), NAV: 29.89 (+0.41), PES: 6.26 (-0.24), MERC: 14.10 (-0.19), GCA: 7.74 (+0.17)

TherapeuticsMD misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 3:25PM CDT

TXMD: 7.17 (+0.01)

TherapeuticsMD Announces Fourth Quarter and Full-Year 2014 Financial Results
Business Wire - Tue Mar 10, 3:09PM CDT
--Cash balance strengthened following recent equity financing of $59.1 million in net proceeds
TXMD: 7.17 (+0.01)

Physicians' Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap
Business Wire - Mon Mar 09, 7:00AM CDT
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, presented at the Endocrine Society's 97th annual meeting new data showing healthcare providers' visual assessments of vulvar and vaginal atrophy (VVA) before and after treatment with the investigational drug TX-004HR in the VagiCap(TM) dosage form correlated with significant changes in vaginal cellular response and pH in postmenopausal women with VVA.
TXMD: 7.17 (+0.01)

Next Week In Biotech: Kythera Ad Comm, Roth Conference, Zogenix Earnings
SA Editor Mike Taylor - at Seeking Alpha - Fri Mar 06, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BDSI: 9.26 (+0.12), OMED: 25.81 (-0.32), BIOA: 10.48 (-0.10), SUPN: 13.67 (-0.10), CTIC: 1.93 (+0.09), ALXA: 2.00 (-0.02), DSCI: 8.45 (-0.16), ANTH: 4.79 (+0.10), CYTX: 0.96 (-0.09), KYTH: 49.94 (+0.78), ANAC: 66.45 (-0.22), ATHX: 1.34 (+0.01), CRMD: 8.86 (-0.28), ACRX: 4.50 (-0.07), TROV: 8.58 (-0.27), ZGNX: 1.63 (-0.02), PETX: 16.15 (+0.01), RPRX: 8.36 (-0.15), IMUC: 0.53 (+0.02), PGNX: 6.33 (-0.12), SNTA: 2.97 (+0.01), BLCM: 28.55 (+2.59), TXMD: 7.17 (+0.01), OGXI: 2.11 (-0.02), AST: 13.61 (-0.11), PLX: 2.08 (+0.02), ATRS: 2.78 (unch)

TherapeuticsMD prices common stock offering at USD4.05 per share
M2 - Thu Feb 12, 4:46AM CST
Healthcare company TherapeuticsMD (NYSE MKT:TXMD) said on Wednesday that it has priced its public offering of 13.6m shares of its common stock.
TXMD: 7.17 (+0.01)

TherapeuticsMD (TXMD) Stock Surges Today After Pricing Public Offering
at The Street - Wed Feb 11, 11:41AM CST
Shares of TherapeuticsMD (TXMD) are up on heavy trading volume after the company priced approximately 13.6 million shares of its common stock at $4.05 per share.
TXMD: 7.17 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...